Related Experiment Video

Updated: Aug 13, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

A protein kinase C inhibitory activity is present in the human T lymphoblast cell line Jurkat

S Columelli1, A M Houllier, J L Pérignon

  • 1Laboratoire de Biochimie, INSERM U75, Faculté de Médecine Necker-Enfants Malades, Paris, France.

Immunology Letters
|November 1, 1991
PubMed

Insights

Researchers discovered a protein inhibitor of protein kinase C (PKC) in Jurkat cells, crucial for studying lymphocyte activation. This inhibitor was absent in normal lymphocytes and leukemic cells.

Area of Science:

  • Cell Biology
  • Biochemistry
  • Immunology

Background:

  • The Jurkat cell line is a key model for lymphocyte activation and signal transduction.
  • Protein Kinase C (PKC) plays a critical role in cellular signaling pathways.

Purpose of the Study:

  • To identify and characterize endogenous inhibitors of Protein Kinase C (PKC) in Jurkat cells.
  • To investigate the presence of PKC inhibitors in normal lymphocytes and leukemic cells.

Main Methods:

  • Cytosolic fractions of Jurkat cells were analyzed for inhibitory activity.
  • Ion-exchange chromatography (DEAE-cellulose) was used to separate the inhibitor from PKC.
  • Reversibility studies were conducted by varying substrate and activator concentrations.

Main Results:

  • A potent, non-diffusible, and thermolabile inhibitor of PKC was identified in Jurkat cell cytosol.
  • The inhibitor's activity was partially reversed by increasing PKC substrate concentration.
  • This specific inhibitory activity was not found in normal lymphocytes or leukemic lymphoblasts.

Conclusions:

  • Jurkat cells possess a unique endogenous inhibitor of PKC, distinct from those in normal or leukemic cells.
  • This inhibitor may play a role in regulating signal transduction in Jurkat cells.
  • The findings suggest potential differences in PKC regulation between Jurkat cells and primary lymphocytes.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...